Global EditionASIA 中文双语Français
Home / World / Americas

China's CoronaVac vaccine gives over 90% protection from ICU admission in Chile: study

Xinhua | Updated: 2021-07-10 18:55
Share - WeChat
A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd, in Beijing, March 16, 2020. [Photo/Xinhua]

SANTIAGO - China's CoronaVac COVID-19 vaccine effectively prevented COVID-19 in Chile, with the adjusted vaccine effectiveness reaching 90.3 percent for the prevention of severe disease, according to a study recently published in the New England Journal of Medicine.

A nationwide mass vaccination campaign was conducted from Feb. 2 to May 1, and a cohort including approximately 10.2 million people aged 16 years and above was used, according to the study titled Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile published on Wednesday.

Among those who were fully immunized, the adjusted vaccine effectiveness was 65.9 percent for the prevention of COVID-19, 87.5 percent for the prevention of hospitalization, and 86.3 percent for the prevention of COVID-19-related death, the results of the study showed.

The CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by Chinese pharmaceutical company Sinovac Biotech.

CoronaVac uses an inactivated whole virus, compelling a recipient's immune system to attack the harmless form of the virus by producing antibodies to fight it off, thus leading to immunity.

Most Viewed in 24 Hours
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349